DelveInsight’s, “Adult-Onset Growth Hormone Deficiency – Pipeline Insight, 2022,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Adult-Onset Growth Hormone Deficiency pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Adult-Onset Growth Hormone Deficiency: Overview
Adult-Onset Growth Hormone Deficiency is a medical condition that occurs when the pituitary gland in brain does not produce enough growth hormone. Most cases of Adult-Onset Growth Hormone Deficiency result from damage to the pituitary gland caused by a pituitary tumor or by treatment for this using surgery and/or radiotherapy. Adult-Onset Growth Hormone Deficiency is treated with growth hormone replacement therapy. The growth hormone that is used is an artificial preparation that individuals can administer themselves.
"Adult-Onset Growth Hormone Deficiency - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adult-Onset Growth Hormone Deficiency pipeline landscape is provided which includes the disease overview and Adult-Onset Growth Hormone Deficiency treatment guidelines. The assessment part of the report embraces, in depth Adult-Onset Growth Hormone Deficiency commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adult-Onset Growth Hormone Deficiency collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Adult-Onset Growth Hormone Deficiency R&D. The therapies under development are focused on novel approaches to treat/improve Adult-Onset Growth Hormone Deficiency.
This segment of the Adult-Onset Growth Hormone Deficiency report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Adult-Onset Growth Hormone Deficiency Emerging Drugs
Sogroya (somapacitan-beco): Novo Nordisk
Somapacitan-beco binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharmacodynamic effects. Some of these pharmacodynamic effects are primarily mediated by insulin-like growth factor I (IGF-I) produced in the liver, while others are primarily a consequence of the direct effects of somapacitan-beco. The drug is registered in USA for the treatment of growth hormone deficiency in adults.
TransCon hGH: Ascendis Pharma
TransCon hGH is an investigational prodrug of somatropin (human growth hormone) in phase 3 development as a once-weekly therapy for children and adults with GHD. TransCon hGH has orphan designation for GHD in both the U.S. and Europe.
Further product details are provided in the report……..
This segment of the report provides insights about the different Adult-Onset Growth Hormone Deficiency drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 3+ key companies which are developing the therapies for Adult-Onset Growth Hormone Deficiency. The companies which have their Adult-Onset Growth Hormone Deficiency drug candidates in the mid to advanced stage, i.e. phase III include, Ascendis Pharma and others.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
Adult-Onset Growth Hormone Deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adult-Onset Growth Hormone Deficiency therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adult-Onset Growth Hormone Deficiency drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Adult-Onset Growth Hormone Deficiency: Overview
Pipeline Therapeutics
Therapeutic Assessment
Adult-Onset Growth Hormone Deficiency – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Adult-Onset Growth Hormone Deficiency Collaboration Deals
Late -stage Products (Phase III)
TransCon hGH: Ascendis Pharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug name: Company name
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Adult-Onset Growth Hormone Deficiency Key Companies
Adult-Onset Growth Hormone Deficiency Key Products
Adult-Onset Growth Hormone Deficiency- Unmet Needs
Adult-Onset Growth Hormone Deficiency- Market Drivers and Barriers
Adult-Onset Growth Hormone Deficiency- Future Perspectives and Conclusion
Adult-Onset Growth Hormone Deficiency Analyst Views
Adult-Onset Growth Hormone Deficiency Key Companies
Appendix
List of Table
Table 1: Total Products for Adult-Onset Growth Hormone Deficiency
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Adult-Onset Growth Hormone Deficiency
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Novo Nordisk
• Ascendis Pharma
